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Abstract
Over 4000 flavonoids have been identified so far and among these, many are known to have antitumor activities. The basis
of the relationships between chemical structures, type and position of substituent groups and the effects these compounds
exert specifically on cancer cells are not completely elucidated. Here we report the differential cytotoxic effects of two
flavone isomers on human cancer cells from breast (MCF7, SK-BR-3), colon (Caco-2, HCT116), pancreas (MIA PaCa, Panc 28),
and prostate (PC3, LNCaP) that vary in differentiation status and tumorigenic potential. These flavones are derived from
plants of the family Asteraceae, genera Gnaphalium and Achyrocline reputed to have anti-cancer properties. Our studies
indicate that 5,7-dihydroxy-3,6,8-trimethoxy-2-phenyl-4H-chromen-4-one (5,7-dihydroxy-3,6,8-trimethoxy flavone) displays
potent activity against more differentiated carcinomas of the colon (Caco-2), and pancreas (Panc28), whereas 3,5-dihydroxy-
6,7,8-trimethoxy-2-phenyl-4H-chromen-4-one (3,5-dihydroxy-6,7,8-trimethoxy flavone) cytototoxic action is observed on
poorly differentiated carcinomas of the colon (HCT116), pancreas (Mia PaCa), and breast (SK-BR3). Both flavones induced cell
death (.50%) as proven by MTT cell viability assay in these cancer cell lines, all of which are regarded as highly tumorigenic.
At the concentrations studied (5–80 mM), neither flavone demonstrated activity against the less tumorigenic cell lines,
breast cancer MCF-7 cells, androgen-responsive LNCaP human prostate cancer line, and androgen-unresponsive PC3
prostate cancer cells. 5,7-dihydroxy-3,6,8-trimethoxy-2-phenyl-4H-chromen-4-one (5,7-dihydroxy-3,6,8-trimethoxy flavone)
displays activity against more differentiated carcinomas of the colon and pancreas, but minimal cytotoxicity on poorly
differentiated carcinomas of these organs. On the contrary, 3,5-dihydroxy-6,7,8-trimethoxy-2-phenyl-4H-chromen-4-one
(3,5-dihydroxy-6,7,8-trimethoxy flavone) is highly cytotoxic to poorly differentiated carcinomas of the colon, pancreas, and
breast with minimal activity against more differentiated carcinomas of the same organs. These differential effects suggest
activation of distinct apoptotic pathways. In conclusion, the specific chemical properties of these two flavone isomers
dictate mechanistic properties which may be relevant when evaluating biological responses to flavones.
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Introduction
There is a group of medicinal plants commonly known in the
Andean regions of South America as vira-viras. These plants
belong to the family Asteraceae, tribe Inuleae, and to the genera
Gnaphalium, Achyrocline, and Gamochaeta [1,2,3]. They are annuals or
perennials that grow between 2000 and 3200 meters above sea
level, to an average height of 1.5 meters. Because of their
morphological characteristics they can easily be confused with
species belonging to different genera. The medicinal use of these
plants is not limited to South America, since similar species
belonging to these genera grow in various parts of the world, and
are commonly used for diverse medicinal purposes. Thus, some
Gnaphalium species are used in poultices to tend wounds, as
a hemostatic, to fight infections, or ease inflammation. For the
cure of cancer, it is recommended in the Andean regions of South
America, the hot beverage obtained by decoction of Gnaphalium
purpureum L., and Gnaphalium elegans H.B.K. [4]. Ethnobotanical
data provide valuable information to further the research and
identification of compounds derived from plants that have been
traditionally used in medicinal preparations by various cultures.
The search for compounds responsible for the therapeutic effects
reported by ethnobotanical studies begins with the sequential
fractionation of extracts derived from specific parts of the plant,
followed by the isolation of molecules present in fractions which
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display biological activity. Among the molecules with highest
therapeutic potential, flavonoids stand out for their extensive range
of pharmacological and biological activities. In vitro and in vivo
studies have shown that flavonoids possess not only cardioprotec-
tive [5,6] anti-inflammatory [7,8], antimicrobial [9,10], antioxi-
dant, anti mutagenic, and anti-tumorigenic activities [11,12], but
are among the most widespread secondary plant metabolites.
Flavonoids potential as antitumor agents is based on mechanisms
that include induction of apoptosis, cell cycle arrest, and
modulation of protein kinase activities [13,14,15] on cancer cells.
Several of these compounds and their derivatives have been
studied in clinical trials, as is the case of genistein, flavopiridol,
catechin, and quercetin [16].
In this study we present the antineoplastic effects of two known
flavone isomers: 5,7-dihydroxy-3,6,8-trimethoxy-2-phenyl-4H-
chromen-4-one (5,7-dihydroxy-3,6,8-trimethoxy flavone or fla-
vone A), and 3,5-dihydroxy-6,7,8-trimethoxy-2-phenyl-4H-chro-
men-4-one (3,5-dihydroxy-6,7,8-trimethoxy flavone or flavone B)
isolated from Gnaphalium elegans [3] and Achyrocline bogotensis [1]
respectively. The anticancer activities of these compounds were
tested on cells derived from cancers of the colon, pancreas, breast,
and prostate with varying tumorigenic and diferentiation status.
The cells were treated using concentrations between 5–80 mM,
which is considered to be the range where most flavonoids exert
physiological activity [13]. The flavones were isolated from
bioactive fractions obtained from the respective plants, then
characterized and tested for purity. Because these compounds
cytotoxic activity is known to specifically target cancer cells while
sparing normal, healthy cells [17], [18], we hypothesized that
these flavone isomers may have differential antineoplastic activities
based on their structure and the tumorigenic potential of the
targeted cells, while minimally affecting normal cells.
Materials and Methods
Cell Culture
Well-differentiated and poorly-differentiated cell lines that
originated in multiple tissue sites were obtained from the
American Tissue Type Culture Collection (ATCC; Manassas,
VA) including: colon (Caco-2, HCT-116), pancreatic (MiaPaca),
breast (MCF-7, SK-BR3), and prostate (LNCaP, PC-3) cell lines.
Human colon normal CCD-112 coN fibroblasts were also
obtained from the ATCC. Tumor cell lines, and normal
fibroblasts were grown in tissue culture according to ATCC
instructions.
The Panc-28 cell line was a gift from Dr. Paul Chiao (University
of Texas M. D. Anderson Cancer Center, Houston, TX) [19], and
was grown in tissue culture in the same manner as pancreatic cell
line Mia PaCa-2, in DMEM with hi-glucose media (GIBCO/
Invitrogen, Carlsbad, CA) supplemented with 10% serum and
penicillin/streptomycin. All cells were seeded and allowed to reach
75% confluency before treatment with flavone A, B or vehicle
(DMSO at a final maximum concentration of 0.01%).
Procedure to obtain 5, 7-dihydroxy-3, 6, 8-trimethoxy
flavone (flavone A)
1.5 kg of G. elegans dried flowers were extracted with CHCl3.
The extract was concentrated by dry vacuum, disolved in
methanol and filtered to eliminate fats and hydrocarbons. The
extract was concentrated and disolved in C6H6, followed by silica
gel chromatography using C6H6:Me2CO (19:1) as eluent. 50 mg
of the flavonoid was purified from fractions 12 through 18 by
crystallizations in hexane. The compound was identified by its
physical and spectroscopic properties as 5,7 dihydroxy-3,6,8
trimethoxy flavone, mp 170–171uC [3], 1H NMR (300 MHz)
3.86 (3H,s), 3.97 (3H,s), 4.20(3H,s), 7.50–7.6 (3H,m), 8.08–8.16
(2H,m) [3].
Procedure to obtain 3, 5-dihydroxy-6, 7, 8-trimethoxy
flavone (flavone B)
200 g of A. bogotensis fresh leaves were submerged in CHCl3 for
20 minutes. The extract was filtered, concentrated and disolved in
hot methanol. The cold extract was filtered to eliminate fats and
was concentrated once again; the obtained solid was disolved in
hot hexane. 100 mg of the purified flavonol was obtained by
successive recrystallizations in hexane. The compound was
identified by its physical and spectroscopic properties as 3,5-
dihydroxy-6,7,8-trimethoxy flavone, mp149–150uC [1], 1H NMR
(300 MHz) 3.86 (3H,s), 3.97 (3H,s), 3.99 (3H,s), 4.12 (3H, s), 7.30–
7.45 (3H,m), 8.70–8.82 (3H,m), 11.46 (1H,s) [1].
MTT assay. Cells were seeded at a density of 4000/well in 48
well plates, grown overnight and treated with either vehicle,
flavone A or flavone B in concentrations of 5, 10, 20, 40, 60,
80 mM; dissolution vehicle was dimethyl sulfoxide to yield
a maximum final concentration of 0.01% in the treated well
(Sigma-Aldrich, St. Louis, MO). After 24 hours of incubation 3-(4,
5-methyl-thiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT)
was added at 100 mg/well for 3 hours (Invitrogen). Formazan
products were solubilized with acidified 2-propanol and optical
density was measured at 570 nm using a Cary 50 (Varian, Palo
Figure 1. Molecular structures of flavones A and B. A. Flavone A was identified by its physical and spectroscopic properties as 5,7 dihydroxy-
3,6,8 trimethoxyflavone. B. Flavone B was identified by its physical and spectroscopic properties as 3,5-dihydroxy-6,7,8-trimethoxyflavone.
doi:10.1371/journal.pone.0039806.g001
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Alto, CA). All experiments were done in triplicate. Data from
assays displaying decrease of cell viability $50%, were evaluated
by nonlinear regression analysis (GraphPad Prism, La Jolla, CA),
and represented as the effective concentration required to decrease
50% of cell viability (EC50). Phase contrast images of the treated
cells were obtained using a Zeiss Axio Observer inverted
microscope, equipped with a Zeiss AxioCam CCD camera.
TUNEL assay. Cells at 75% confluency were treated with
40mM flavone A, flavone B, or vehicle (DMSO at a maximum
final concentration of 0.01%) for 90 minutes. The cells were fixed
with 4% paraformaldehyde and permeabilized with 0.1% sodium
citrate and 0.1% Triton X. DNA fragmentation was determined
by TdT-mediated dUTP nick end labeling (TUNEL) as described
by the manufacturer (Roche Applied Science, Mannheim,
Germany). Fluorescent images were obtained using an EVOS
fluorescent microscope (AMG, Bothell, WA).
Data Treatment and Statistical Analysis
Data were analyzed for significant difference using two-way
ANOVAs with compound and concentration as factors. Signifi-
cant main effects were followed with Bonferroni-Holm post hoc
tests (SAS 9.2; SAS Institute, Cary, NC). Statistical significance
was set at p,0.05.
Results
Flavone A and flavone B are known isomers
Flavone A derived from Gnaphalium elegans and previously
described by Torrenegra et al., [3] as 5,7 dihydroxy-3,6,8
trimethoxy flavone, and flavone B derived from Achyrocline bogotensis
and previously described by Torrenegra et al., [1] as 3,5-
dihydroxy-6,7,8-trimethoxy flavone, are isomers as shown in
figure 1. The hydroxyl group in position 7, and the methoxyl
group in position 3 in flavone A are switched with a methoxy and
hydroxyl groups respectively in flavone B.
Flavone A but not flavone B greatly decreases cell
viability of Caco-2 human colon cancer cells
To determine whether the flavones where cytotoxic to colon
cancer, the cells (figures 2A and B) were treated with either one of
the compounds. Flavone A effectively decreased cell viability of the
more differentiated Caco-2 cells in a concentration-dependant
manner, as indicated by MTT assays. Flavone B exerts a markedly
lesser effect on these cells as shown in figure 2A. This is evidenced
by a half maximal effective concentration (EC50), for flavone A of
12.42 mM versus 74.82 mM for flavone B (figure 2C). Images of
Figure 2. Comparison of the effects of flavone A and flavone B on human colon cancer Caco-2 and HCT-116 cells. The effects of
flavone A and flavone B on the more differentiated colon cancer Caco-2 cells (A), and the poorly differentiated colon cancer HCT-116 cells (B) were
determined by MTT assay and are represented as a percent of the control absorbance at a wavelength of 570 nm. All data were collected at 24 h after
treatment. Data shown are from representative experiments (n = 3). Values are expressed as mean 6 SE, * p,0.05, significant difference between
control and other concentrations for each flavone. # p,0.05, significant difference between flavone A and flavone B treated cells at similar
concentrations. C. Half maximal effective concentration (EC50) 6 SE for flavone A and flavone B treatment on colon carcinoma and cells. The values
were estimated by non-linear regression analysis. D. Representative phase contrast images of colon carcinoma Caco-2 cells and colon carcinoma HCT-
116 (E.) cells, 24 hours after treatment with flavone A and flavone B at 5, 10, 20, 40 and 80 mM, or treated with vehicle (0 mM of flavone A or B).
doi:10.1371/journal.pone.0039806.g002
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Caco-2 cells treated with increasing concentrations of flavone A,
show progressive cell death (figure 2D).
Flavone B but not flavone A greatly decreases cell
viability of poorly differentiated HCT-116 human colon
cancer cells
Flavone B effectively decreased cell viability of HCT-116 cells as
indicated by MTT assays, while flavone A has a minimal effect, as
shown in figure 2B. The half maximal effective concentration
(EC50) for flavone B is 37.50 mM, and 69.99 mM for flavone A
(figure 2C). Images of colon carcinoma (HCT-116) cells treated
with increasing concentrations of flavone B, display a gradual
decrease of cell viability (figure 2E).
Flavone A but not flavone B is cytotoxic to Panc28
human pancreatic cancer cells
To determine whether the flavones where cytotoxic to pancreas
cancer cells (figures 3A and B), we treated the cells with either one
of the compounds. Flavone A significantly decreased the cell
viability of the more differentiated Panc28 cells as indicated by
MTT cell survival assays, whereas flavone B had no effect at this
concentration range (figure 3A). The half maximal effective
concentration (EC50) for flavone A on Panc28 cells is 51.76 mM
(figure 3C). Images of Panc28 cells treated with flavone A depict
progressive cell death at increasing concentrations (figure 3D).
Flavone B but not flavone A is cytotoxic to poorly
differentiated MIA PaCa human pancreatic cancer cells
Based on MTT assays, flavone B is cytotoxic to MIA PaCa cells,
but not flavone A (figure 3B). The half maximal effective
concentration (EC50) for flavone A on MIA PaCa cells is
33.18 mM (figure 3C). Images of decreasing cell viability of
pancreatic carcinoma (MIA PaCa) cells treated with increasing
concentrations of flavone B for 24 hours are shown in figure 3E.
Neither flavone A nor flavone B has an effect on the more
differentiated MCF-7 human breast cancer cells; but
flavone B has a marked inhibitory effect on the poorly
differentiated SK-BR3 breast cancer cells
To determine whether the flavones where cytotoxic to breast
cancer cells, we treated the cells with either one of the compounds.
MTT cell viability assays of estrogen receptor and progesterone
receptor positive (ER+/PR+) MCF7 cells (figure 4A) treated with
flavones A and B demonstrate the absence of an effect on cell
Figure 3. Comparison of the effects of flavone A and flavone B on pancreatic cancer Panc28 and MIA PaCa cells. The effects of flavone
A and flavone B on the more differentiated pancreatic cancer Panc28 (A), and the poorly differentiated pancreatic cancer MIA PaCa cells (B) were
determined by MTT assay and are represented as a percent of the control absorbance at a wavelength of 570 nm. All data were collected at 24 h after
treatment. Data shown are from representative experiments (mean 6 SE, n = 3). * p,0.05, significant difference between control and other
concentrations for each flavone. # p,0.05, significant difference between flavone A and flavone B treated cells at similar concentrations. C. Half
maximal effective concentration (EC50) 6 SE for flavone A and flavone B treatment on Panc28 and MIA PaCa cells. The values were estimated by non-
linear regression analysis. D. Representative phase contrast images of pancreatic cancer Panc28 and MIA PaCa cells (E.) 24 hours after treatment with
flavone A and flavone B at 5, 10, 20, 40 and 80 mM, or treated with vehicle (0 mM of flavone A or B).
doi:10.1371/journal.pone.0039806.g003
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survival. Figure 4B shows flavone B effectively decreases cell
viability on receptor negative (ER¯/PR¯), poorly differentiated SK-
BR3 human breast cancer cells, with a half maximal effective
concentration of 11.06 mM (figure 4C).
Neither Flavone A nor flavone B is cytotoxic to human
prostate carcinoma LNCaP and PC3 cells
To determine whether the flavones where cytotoxic to prostate
cancer cells, we treated the cells with either one of the compounds.
Flavone A and flavone B failed to decrease cell viability of the
more differentiated [20–21] androgen-responsive LNCaP cells
(figure 5A), as well as the poorly differentiated [22] PC3 androgen
receptor negative cells (figure 5B) as indicated by MTT assay.
Neither flavone A nor flavone B is cytotoxic to normal
fibroblasts
To determine whether the flavones were cytotoxic to normal
cells, we treated normal fibroblasts with either one of the
compounds. Cell viability of normal colon fibroblasts CCD-112
coN, is unaffected by either flavone as shown by MTT assay after
a 24 hour treatment with increasing concentrations of the
compounds between 5–80 mM (figure 5C).
The apoptotic effects of flavone A and flavone B, were
confirmed via TUNEL assay as shown on figure 6 on Caco-2,
Panc 28, and MIA PaCa cells.
Discussion
Gnaphalium elegans and Achyrocline bogotensis were selected for their
medicinal properties reported in ethnobotanical studies [4]. These
plants are indigenous to the Andean region of South America, but
have successfully undergone preliminary domestication studies.
The flavones presented in this study are not exclusive to plants
native to this geographic location. Flavone A has been isolated
from Ainsliaea henryi, native to the southern and western portions of
China [23]. Tomas-Lorente et al., has reported that flavone A was
extracted from Helichrysum decumbens along with two other
methylated flavonoids [24] Flavone B has been found in
Helichrysum graveolens [25], Helichrysum odoratissimum [26] and
Helichrysum compactum [27]. The plant extracts of the latter
demonstrated to have antibacterial and antioxidant activities.
Medicinal plants belonging to the genus Helichrysum, traditionally
have been used in Rwanda and other African countries for their
antibacterial, antitussive, and sedative properties. Research on the
therapeutic use of flavonoids has advanced greatly in the last ten
years, and some compounds are being tested in clinical trials.
Our findings identify flavone A and its isomer flavone B, as
potential anti-tumor agents. Indeed, these compounds display
cytotoxic activity against cell lines that have been categorized as
being highly tumorigenic. High-expression levels of Aldehyde
dehydrogenase (ALDH) is regarded as a very specific marker used
in the detection of cancer-initiating cells as subpopulations in
tumors, [28,29,30,31,32,33] as well as in the determination of
tumorigenic status in established cancer cell lines. Flavone A and
flavone B cytotoxic activity is directed towards highly tumorigenic
cells that express high levels of ALDH: Caco-2 and HCT-116
[34,35], as well as pancreatic cancer Panc28 and MIA PaCa, [36],
and breast cancer SK-BR3 [37] cells. On the contrary, Flavone A
and B activities were observed to be significantly diminished in less
tumorigenic cells, characterized by low expression levels of ALDH:
breast cancer MCF7 cells [34,37], and prostate cancer PC3and
LNCaP cells [38].
Cancer cell lines display variability in regards to differentiation
status. Thus, more differentiated cells can be distinguished from
Figure 4. Comparison of the effects of flavone A and flavone B on breast cancer MCF7 and SK-BR3 cells. The effects of flavone A and
flavone B on the more differentiated breast cancer MCF7 (A), and the poorly differentiated breast cancer Sk-BR3 cells (B) were determined by MTT
assay and are represented as a percent of the control absorbance at a wavelength of 570 nm. All data were collected at 24 h after treatment. Data
shown are from representative experiments (mean 6 SE, n = 3). * p,0.05, significant difference between control and other concentrations for each
flavone. # p,0.05, significant difference between flavone A and flavone B treated cells at similar concentrations. C. Half maximal effective
concentration (EC50) 6 SE for flavone A and flavone B treatment on MCF7 and SK-BR3 cells. The values were estimated by non-linear regression
analysis.
doi:10.1371/journal.pone.0039806.g004
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poorly differentiated cells by the presence of specific polarity and
differentiation markers, as well as doubling time. Among these
highly tumorigenic cells upon which the flavones activity is
targeted, we find that flavone A has a preferential effect on the
more differentiated colon cancer Caco-2 [39] cells, and pancreatic
cancer Panc28 cells. It is important to note that the latter has been
classified as poorly differentiated when polarity markers are
compared with better differentiated pancreatic cancer cells such as
Capan-1. However, it is the general consensus that Panc28 cells
possess a higher differentiation status than MIA PaCa cells,
specifically when doubling time is considered [40]. Our results
suggest that flavone A has a preference for the more-differentiated
colon carcinoma Caco-2 cells and pancreatic cancer Panc28 cells
as compared to greatly diminished activity on poorly differentiated
cells. On the contrary, flavone B displays preferential activity
towards poorly differentiated cancer cells of the colon (HCT-116),
pancreas (MIA PaCa) and cadherin negative breast cancer SK-
BR3 cells [41].
In line with previous reports [13], neither flavone A nor flavone
B is cytotoxic to normal cells. However, it has been shown that this
lack of cytotoxic activity on normal cells while targeting malignant
cells, has several exceptions as is the case of the hydroxyflavones
luteolin and apigenin. Recent studies conducted on methoxylated
hydroxyflavones suggest that the presence of sequential methoxy-
lated groups, as observed in flavone B, may dictate lack of
cytotoxic activity on normal cells [42]. Extensive studies indicate
that certain substitution patterns in flavones may increase their
anticancer activity. These observations may benefit from addi-
tional information in regards to characteristics that may serve to
categorize cancer cell lines prone to anticancer activity. In these
flavone isomers, the positions of –OH and –OCH3 groups not
only alter the conformation but also the charge delocalization of
the compounds, which may be relevant to cellular uptake. In
flavone A, both 5- and 7-OH can resonate with the carbonyl, but
the 5-OH next to the carbonyl has one more resonance structure.
In flavone B, the 5-OH can resonate with the carbonyl but not the
3-OH. While optimization of these structures is yet to be obtained
and analyzed, charge delocalization and resonance as a result of
the position of substituents are likely to influence anti cancer
activities.
At the cellular level, our results suggest an appreciable degree of
neoplastic specificity. The preferential effect of these two isomers
on cancers with varying differentiation status, suggest a bifurcation
in the mechanisms of action of these compounds that may afford
new insights on the study of these malignancies. Specific and
effective growth inhibition of cancer cells by these compounds may
provide alternative therapies urgently needed in highly aggressive
Figure 5. Absence of significant effect on cell viability of flavone A and flavone on prostate cancer LNCaP and PC3 cells as well as
on normal human colon fibroblasts (CCD-112 coN). The effects of flavone A and flavone B on the more differentiated prostate cancer LNCaP
(A), and the less differentiated PC3 cancer cells (B) were determined by MTT assay and are represented as a percent of the control absorbance at
a wavelength of 570 nm. All data were collected at 24 h after treatment. Data shown are from representative experiments (mean 6 SE, n = 3). *
p,0.05, significant difference between control and other concentrations for each flavone. # p,0.05, significant difference between flavone A and
flavone B treated cells at similar concentrations. In the same manner as described above, the effects of flavone A and flavone B normal human colon
fibroblasts (C) were determined by MTT assay.
doi:10.1371/journal.pone.0039806.g005
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Figure 6. TUNEL assay. A. Apoptotic effect of flavone A at a concentration of 40 mM, on the more differentiated colon cancer Caco-2 cells, as
determined by TUNEL assay (green channel) 90 minutes after treatment. DAPI (blue channel) is used to locate the nuclei of the cells. B. Colon Caco-2
cells treated with vehicle only (DMSO at a final concentration of 0.01%) served as a control. TUNEL assay was conducted 90 minutes after treatment.
C. Activation of apoptosis on the more differentiated pancreatic cancer Panc28 cells by flavone A at a concentration of 40 mM, as determined by
TUNEL assay (green channel) 90 minutes after treatment. DAPI is used to locate the nuclei of the cells. D. As a control, pancreatic cancer Panc28 cells
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neoplasias such as pancreatic cancer which continues to have
a very low five year survival rate.
Recent reports have shown the use of flavonoids to augment the
effectiveness of existing oncology medications [28,39,43]. The
process by which these compounds are able to effectively induce
the activation apoptosis in cancer cells is also of great interest
[30,31]. The differential effects described in this study, suggest
activation of distinct apoptotic pathways. Initial studies on the
mechanism of action of these compounds, however, indicate that
both induce apoptosis via the activation of the intrinsic caspase
cascade. TUNEL assay which specifically detects apoptosis was
carried out 1.5–4 hours after treatment with the flavones or
vehicle, due to parallel occurrence of apoptosis activation and
cellular detachment (figure 6). These observations suggest that
these compounds may interfere shortly after treatment with
signaling pathways associated with cell-matrix and cell-cell
adhesion molecules, as apoptosis takes place. Investigation in the
mechanisms of activation upstream of the activation of caspases is
necessary to better understand the potential use of these
compounds in novel antineoplastic therapies.
This study presents two flavone isomers that may be responsible
for the anticancer activities associated to Gnaphalium elegans and
Achyrocline bogotensis. We also present evidence that suggest that
these compounds display preferential targeting which may depend
upon cellular tumorigenic and differentiation status. Further
studies are necessary to elucidate the mechanisms responsible for
the observed differential effects.
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